國立虎尾科技大學 |

Immunotherapy

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Immunotherapy/ edited by Aung Naing, Joud Hajjar.
其他作者:	Hajjar, Joud.
面頁冊數:	VIII, 447 p. 41 illus., 32 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer Research. -
電子資源:	https://doi.org/10.1007/978-3-030-79308-1
ISBN:	9783030793081

Immunotherapy
Immunotherapy[electronic resource] /edited by Aung Naing, Joud Hajjar. - 4th ed. 2021. - VIII, 447 p. 41 illus., 32 illus. in color.online resource. - Advances in Experimental Medicine and Biology,13422214-8019 ;. - Advances in Experimental Medicine and Biology,889.

Immune System in Action -- 2. Resistance to Immunotherapy: Mechanisms and Means for Overcoming -- 3. Immunotherapy for Melanoma -- 4. Immunotherapy in Lung Cancer: Are the promises of long-term benefit finally met? -- 5. Landscape of Immunotherapy in Genitourinary Malignancies -- 6. Immuno-oncology for Gynecologic Malignancies -- 7. Immunotherapy for Neuro-oncology -- 8. Immunotherapy in Gastrointestinal Malignancies -- 9. An update on immune based therapies in acute myeloid leukemia: 2021 and beyond! -- 10. CAR T-cells -- 11. Skin Reactions to Immune Checkpoint Inhibitors -- 12. Immunotherapy Mediated luminal Gastrointestinal toxicities -- 13. Hepatobiliary and Pancreatic Adverse Events -- 14. Pulmonary toxicities of immunotherapy -- 15. Immune checkpoint inhibitors (ICIs) related cardiotoxicity -- 16. Renal Toxicity -- 17. Immune-Related Oral, Otologic and Ocular Adverse Events -- 18. Neurologic Toxicities of Immunotherapy -- 19. Cancer Imaging in Immunotherapy. .

The field of immuno-oncology continues to rapidly evolve as new insights to fight and treat cancer emerge. The fourth edition of Immunotherapy provides the most current overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. While immunotherapy has revolutionized the treatment landscape of several solid malignancies, several challenges still exist. Only a subset of patients derive clinical benefits; some do not respond at all, and others respond initially, only for their disease to progress later. Because these drugs can activate a broad range of immune cells, patients suffer from a unique set of side effects known as immune-related adverse events. As more immunotherapeutic agents are used in the clinic, it is important to provide updates about current and ongoing developments in the field to further research efforts and inform treatment decisions. The fourth edition will have a new focus on strategies to overcome the challenges associated with immunotherapy. Chapters will discuss topics such as biomarkers of response, resistance mechanisms, role of imaging in predicting immune-related adverse events, and management of immune-related adverse events. Written by leading experts conducting cutting-edge research, readers will gain up-to-date knowledge on the current state and future of immunotherapy. .

ISBN: 9783030793081

Standard No.: 10.1007/978-3-030-79308-1doiSubjects--Topical Terms:

668358
Cancer Research.

LC Class. No.: QR180-189.5

Dewey Class. No.: 616.079

Immunotherapy
LDR:03725nam a22003975i 4500 001 1057815
003 DE-He213
005 20211220123156.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030793081 $9 978-3-030-79308-1
024 7 $a 10.1007/978-3-030-79308-1 $2 doi
035 $a 978-3-030-79308-1
050 4 $a QR180-189.5
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.079 $2 23
245 1 0 $a Immunotherapy $h [electronic resource] / $c edited by Aung Naing, Joud Hajjar.
250 $a 4th ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a VIII, 447 p. 41 illus., 32 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Advances in Experimental Medicine and Biology, $x 2214-8019 ; $v 1342
505 0 $a Immune System in Action -- 2. Resistance to Immunotherapy: Mechanisms and Means for Overcoming -- 3. Immunotherapy for Melanoma -- 4. Immunotherapy in Lung Cancer: Are the promises of long-term benefit finally met? -- 5. Landscape of Immunotherapy in Genitourinary Malignancies -- 6. Immuno-oncology for Gynecologic Malignancies -- 7. Immunotherapy for Neuro-oncology -- 8. Immunotherapy in Gastrointestinal Malignancies -- 9. An update on immune based therapies in acute myeloid leukemia: 2021 and beyond! -- 10. CAR T-cells -- 11. Skin Reactions to Immune Checkpoint Inhibitors -- 12. Immunotherapy Mediated luminal Gastrointestinal toxicities -- 13. Hepatobiliary and Pancreatic Adverse Events -- 14. Pulmonary toxicities of immunotherapy -- 15. Immune checkpoint inhibitors (ICIs) related cardiotoxicity -- 16. Renal Toxicity -- 17. Immune-Related Oral, Otologic and Ocular Adverse Events -- 18. Neurologic Toxicities of Immunotherapy -- 19. Cancer Imaging in Immunotherapy. .
520 $a The field of immuno-oncology continues to rapidly evolve as new insights to fight and treat cancer emerge. The fourth edition of Immunotherapy provides the most current overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. While immunotherapy has revolutionized the treatment landscape of several solid malignancies, several challenges still exist. Only a subset of patients derive clinical benefits; some do not respond at all, and others respond initially, only for their disease to progress later. Because these drugs can activate a broad range of immune cells, patients suffer from a unique set of side effects known as immune-related adverse events. As more immunotherapeutic agents are used in the clinic, it is important to provide updates about current and ongoing developments in the field to further research efforts and inform treatment decisions. The fourth edition will have a new focus on strategies to overcome the challenges associated with immunotherapy. Chapters will discuss topics such as biomarkers of response, resistance mechanisms, role of imaging in predicting immune-related adverse events, and management of immune-related adverse events. Written by leading experts conducting cutting-edge research, readers will gain up-to-date knowledge on the current state and future of immunotherapy. .
650 2 4 $a Cancer Research. $3 668358
650 0 $a Cancer research. $3 1253664
650 0 $a Immunology. $3 592892
700 1 $a Hajjar, Joud. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1139516
700 1 $a Naing, Aung. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1139515
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030793074
776 0 8 $i Printed edition: $z 9783030793098
830 0 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 889 $3 1253792
856 4 0 $u https://doi.org/10.1007/978-3-030-79308-1
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)